BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Long-term Investments
Investments the company intends to hold for more than a year.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Long-term Investments · Q1 FY2026 · quarter ended Mar 2026
Long-term investments remains negative
Q1 FY2026 long-term investments was $136.75M, compared with $0 a year earlier.
Context
- Long-term investments amounted to 32.7% of total assets at the end of Q1 FY2026, up 32.7 pp from a year earlier.
- Long-term investments increased in 1 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 132K USD
- Year-over-year change
- -99.9%
| Period | Period end | Long-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 132K | -99.9% |
| FY2024 | 2024-12-31 | 192.45M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Long-term Investments vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so long-term investments is compared through growth and share of total assets rather than absolute size.
- Long-term investments amounts to 32.7% of total assets for BBOT, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $136.75M USD | — | — | 32.7% |
| Jun 2026 | $108.54M USD | -58.3% | +44.6% | 15.0% | |
| Aug 2026 | $14.83M USD | — | — | 1.2% | |
| Sep 2026 | $3.95M USD | -36.2% | -0.7% | 1.9% | |
| Mar 2026 | $177K USD | -96.1% | — | 0.1% | |
| Sep 2026 | $0 USD | — | — | 0.0% | |
SEPNSepterna, Inc. | Sep 2026 | $0 USD | -100.0% | — | 0.0% |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | CHF 0 CHF | — | — | 0.0% | |
| Peer median (excluding BBOT) | — | -98.0% | +21.9% | 0.0% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.